- 1 A new preprocedural predictive risk model for post-endoscopic retrograde
- 2 cholangiopancreatography pancreatitis: The SuPER model
- 4 Mitsuru Sugimoto^{1*}, Tadayuki Takagi¹, Tomohiro Suzuki², Hiroshi Shimizu², Goro
- 5 Shibukawa³, Yuki Nakajima³, Yutaro Takeda⁴, Yuki Noguchi MD⁴, Reiko Kobayashi
- 6 MD⁴, Hidemichi Imamura⁴, Hiroyuki Asama⁵, Naoki Konno⁵, Yuichi Waragai⁶,
- Hidenobu Akatsuka⁷, Rei Suzuki¹, Takuto Hikichi⁸, and Hiromasa Ohira¹
- ¹Department of Gastroenterology, Fukushima Medical University, School of Medicine,
- 10 Fukushima, Japan

- ²Department of Gastroenterology, Fukushima Rosai Hospital, Iwaki, Japan
- ³Department of Gastroenterology, Aizu Medical Center, Fukushima Medical University,
- 13 Aizu, Japan
- ⁴Department of Gastroenterology, Ohta Nishinouchi Hospital, Koriyama, Japan
- ⁵Department of Gastroenterology, Fukushima Redcross Hospital, Fukushima, Japan
- ⁶Department of Gastroenterology, Soma General Hospital, Soma, Japan
- ⁷Department of Gastroenterology, Saiseikai Fukushima General Hospital, Fukushima,
- 18 Japan

19	⁸ Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan
20	
21	* For correspondence
22	kita335@fmu.ac.jp
23	

25 **Abstract** 26 **Background:** Post–endoscopic retrograde cholangiopancreatography (ERCP) 27 pancreatitis (PEP) is a severe and deadly adverse event following ERCP. The ideal 28 method for predicting PEP risk before ERCP has yet to be identified. We aimed to 29 establish a simple PEP risk score model (SuPER model: Support for PEP Reduction) that can be applied before ERCP. 30 **Methods**: This multicenter study enrolled 2074 patients who underwent ERCP. Among 31 them, 1037 patients each were randomly assigned to the development and validation 32 33 cohorts. In the development cohort, the risk score model for predicting PEP was 34 established by logistic regression analysis. In the validation cohort, the performance of 35 the model was assessed. **Results:** In the development cohort, five PEP risk factors that could be identified before 36 37 ERCP were extracted and assigned weights according to their respective regression coefficients: -2 points for pancreatic calcification, 1 point for female sex, and 2 points 38 39 for intraductal papillary mucinous neoplasm, a native papilla of Vater, or the use of pancreatic duct procedures. The PEP occurrence rate was 0% among low-risk patients 40 $(\le 0 \text{ points})$, 5.5% among moderate-risk patients (1 to 3 points), and 20.2% among 41 42high-risk patients (4 to 7 points). In the validation cohort, the C-statistic of the risk score

model was 0.71 (95% CI 0.64-0.78), which was considered acceptable. The PEP risk

classification (low, moderate, and high) was a significant predictive factor for PEP that
was independent from intraprocedural PEP risk factors (precut sphincterotomy and
inadvertent pancreatic duct cannulation) (OR 4.2, 95% CI 2.8-6.3, *P* < 0.01).

Conclusions: The PEP risk score allows an estimation of the risk of PEP prior to ERCP,
regardless of whether the patient has undergone pancreatic duct procedures. This simple
risk model, consisting of only five items, may aid in predicting and explaining the risk
of PEP before ERCP and in preventing PEP by allowing selection of the appropriate

expert endoscopist and useful PEP prophylaxes.

51

Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Endoscopic retrograde cholangiopancreatography (ERCP) is widely performed as an important diagnostic and therapeutic procedure for pancreaticobiliary diseases. ERCP-related procedures are relatively risky among endoscopic procedures. The high-risk adverse events of ERCP include duodenal perforation and bleeding after endoscopic sphincterotomy (EST) and post-ERCP pancreatitis (PEP). The rate of PEP occurrence is 3.1-13.0% (Andriulli et al., 2007, Freeman et al., 1996, Glomsaker et al., 2013, Katsinelos et al., 2014, Kochar et al., 2015, Loperfido et al., 1998). PEP can even become life-threatening. The fatality rate of PEP is 0.1-0.7% (Andriulli et al., 2007, Kochar et al., 2015). Therefore, the decision to perform ERCP should be made carefully, considering each patient's risk factors for PEP. To predict an individual patient's PEP risk, five scoring systems have been devised (Chiba et al., 2021, DiMagno et al., 2013, Friedland et al., 2002, Fujita et al., 2021, Zheng et al., 2020). The first risk scoring system for PEP occurrence was established in 2002. In that study, pain during the procedure, pancreatic duct cannulation, a history of PEP, and the number of cannulation attempts were identified as risk factors for PEP. After the first scoring system was reported, each new scoring system used risk factors that were extracted by multivariate analyses. These included various patient characteristics before ERCP and postprocedural risk factors. As

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

postprocedural risk factors, precut sphincterotomy and difficult cannulation were proposed, but it is difficult to predict these risk factors and to determine the PEP risk before ERCP. Thus, a new prediction scoring system for PEP before ERCP is desirable. If the risk of PEP could be predicted before ERCP, then the expert endoscopist can perform ERCP from the start, and high-PEP-risk procedures (for example, precut sphincterotomy, multiple cannulation attempts, inadvertent pancreatic duct cannulation) can be avoided (Testoni et al., 2010, Wang et al., 2009). If biliary cannulation without the use of at least one high-PEP-risk procedure is difficult, other treatments (for example, percutaneous transhepatic biliary drainage (PTBD) or endoscopic ultrasound (EUS)-guided biliary drainage (EUS-BD)) could be considered. Therefore, we aimed to establish a PEP prediction model using only risk factors that can be gathered before ERCP. Our model was developed and validated with multicenter data from Japan. Methods We performed a multicenter retrospective study at six institutions in Japan. This study was approved by the institutional review board of Fukushima Medical University and that of each partner medical institution. All patients agreed to undergo ERCP after

providing written consent. 90 91 92 **Patients** 93 Among 2,176 patients who underwent ERCP between November 2020 and October 2022, 2,074 were enrolled in this study. The other 102 patients were excluded for the 94 following reasons: past history of choledochojejunostomy, acute pancreatitis, 95 96 choledochoduodenal fistula, difficulty finding the Vater papilla, past history of pancreatojejunostomy, or past history of pancreatogastrostomy (Figure 1). 97 98 Study design 99 100 We randomly sampled 50% of the patients as the development cohort and 50% as the 101 validation cohort (**Figure 1**). In the development cohort, we established a risk scoring system for predicting PEP before ERCP, which was named the support for PEP 102 103 reduction model (SuPER model). The validation cohort was used to confirm the 104 effectiveness of the scoring system. PEP diagnosis and severity were assessed according 105 to Cotton's criteria (Cotton et al., 1991). Patients who experienced abdominal pain and 106 had hyperamylasemia (more than three times the normal upper limit) at least 24 hours 107 after ERCP were diagnosed with PEP. Mild PEP was defined as pancreatitis that

required prolongation of the planned hospitalization by 2-3 days. Moderate PEP was defined as pancreatitis that required 4-10 days of hospitalization. Severe PEP was defined as pancreatitis that required more than 10 days of hospitalization or intervention or hemorrhagic pancreatitis, phlegmon, or pseudocysts.

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

To establish the risk score, the risk factors for PEP were investigated using the data from the development cohort. To determine the PEP risk score, factors that might be associated with PEP occurrence were investigated. To predict the PEP risk score before ERCP, factors related to patient characteristics and previously scheduled procedures, as reported in past studies, were selected. The patients' risk factors included age < 50 years, female sex, a past history of pancreatitis, a past history of PEP, a past history of gastrectomy, pancreatic cancer, intraductal papillary mucinous neoplasm (IPMN), a native papilla of Vater, absence of chronic pancreatitis (CP), normal serum bilirubin ($\leq 1.2 \text{ mg/dl}$), and periampullary diverticulum (Ding et al., 2015, Freeman et al., 2001, Freeman et al., 1996, Fujita et al., 2022, Fujita et al., 2021, Masci et al., 2003, Wang et al., 2009, Williams et al., 2007, Zheng et al., 2020). Pancreatic divisum was excluded from the patient risk factor list because pancreatic divisum was observed in only two patients. Pancreatic calcification and a diameter of the main pancreatic duct > 3 mm were considered to indicate CP (Beyer et al., 2023, Sarner and Cotton, 1984).

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

These imaging findings were confirmed by CT, MRI, or EUS before ERCP. The CT and MRI findings were reviewed by radiologists. IPMN was diagnosed according to the results of CT, MRI, and EUS. As pre-ERCP prophylaxes for PEP, gabexate or nafamostat, intravenous hydration, and NSAID suppositories were used (Fujita et al., 2022). As planned procedure-related risk factors, EST, endoscopic papillary balloon dilation (EPBD), endoscopic papillary large balloon dilation (EPLBD) using a ≥ 12 mm balloon catheter (Itoi et al., 2018), biliary stone removal, ampullectomy, biliary stent material (plastic stent, self-expandable metallic stent (SEMS), or covered SEMS (CSEMS)), inside stent placement, and procedures on the pancreatic duct were evaluated (Freeman et al., 2001, Freeman et al., 1996, Harewood et al., 2005, Kato et al., 2022, Masci et al., 2003, Masci et al., 2001, Testoni et al., 2010, Williams et al., 2007). A biliary stent above the Vater papilla was also assessed as a prophylactic measure against PEP (Ishiwatari et al., 2013). To demonstrate the independence of the established risk classification, the relationship between it and intraprocedural PEP risk factors (including precut sphincterotomy and inadvertent pancreatic duct cannulation) (Testoni et al., 2010, Wang et al., 2009) were investigated. Because of the retrospective nature of the data, the exact cannulation times and the number of cannulation attempts were not available.

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

Therefore, multiple cannulation attempts and a prolonged cannulation time could not be investigated as intraprocedural PEP risk factors. Sample size The primary aim of this study was to establish a PEP prediction model that could be used to calculate a risk score before ERCP. To construct a prediction model by logistic regression analysis, 10 events per explanatory variable were needed (Wynants et al., 2015). Seven variables were evaluated in the development cohort, so 70 PEP patients were required. Five variables were evaluated in the validation cohort, so 50 PEP patients were necessary for it. According to a previous systematic review, the rate of PEP occurrence was 9.7% (Kochar et al., 2015). Therefore, at least 722 and 521 patients were included in the development and validation cohorts, respectively. Statistical analysis In the development cohort, univariate and multivariate logistic regression analyses were performed to identify the risk factors for PEP. The factors that had a p value < 0.10 in the univariate analysis were included in the multivariate analysis. To construct the scoring system for PEP risk, the factors with p < 0.10 in the multivariate analysis were

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

ultimately included in the risk score model. The factors selected in the multivariate analysis were assigned points according to the regression coefficient (each variable's risk points = the ratio of the variable's regression coefficient/minimum regression coefficient). The sum of the assigned points was calculated for each patient, and the patients were classified into three groups (low risk, moderate risk, and high risk) according to the expected rate of PEP occurrence (Friedland et al., 2002). The risk classification system (SuPER model) was also applied to the validation cohort. With respect to both the development and validation cohorts, the effectiveness of the risk score model was evaluated as follows. The correlations between the risk score, risk classification and PEP occurrence were evaluated by the Cochran-Armitage trend test. The predictive accuracy of the risk score was assessed using the C statistic. The goodness of fit of the model was evaluated using the Hosmer-Lemeshow test. The independence of the established risk classification from the unexpected intraprocedural PEP risk factors was assessed by multivariate logistic regression analyses. Patients with missing data for variables selected in the risk score model were removed from the final cohort. Statistical analyses were performed using EZR version 1.62 (Saitama Medical

Centre, Jichi Medical University, Saitama, Japan) and SPSS version 26.0 (IBM Corp.,

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Armonk, NY, USA). A p value < 0.05 indicated statistical significance. **Results** Patient characteristics and ERCP outcomes in each cohort The patient characteristics and ERCP outcomes in each cohort are shown in Table 1. A total of 1037 patients were assigned to each of the development and validation cohorts, including 70 (6.8%) and 64 (6.2%) patients diagnosed with PEP, respectively. The pre-ERCP prophylactic measures used at each hospital differed, and not all patients received prophylaxis. Construction of the PEP risk scoring system According to the univariate analyses, age < 50 years, female sex, IPMN, a native papilla of Vater, pancreatic calcification, EST, and procedures on the pancreatic duct had p values < 0.10 (**Table 2**). According to the multivariate analysis, female sex, IPMN, a native papilla of Vater, pancreatic calcification, and procedures on the pancreatic duct had p values < 0.10. These factors were assigned risk points according to their respective regression coefficients.

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

The risk score of each patient was calculated as the total of that patient's risk points and ranged from -2 to 7 points (Table 3). The risk score was found to be correlated with PEP occurrence (p < 0.01, Cochran–Armitage trend test). The patients were classified as low (≤ 0 points), moderate (1-3 points), or high risk (4-7 points) for PEP according to the risk score. The PEP rates were 0% (0/327) among the low-risk patients, 5.5% (27/492) among the moderate-risk patients, and 20.2% (39/193) among the high-risk patients. The risk classification was correlated with PEP occurrence (p <0.01, Cochran–Armitage trend test). The C statistic of the risk score model was sufficiently high at 0.77 (95% confidence interval (CI) 0.72-0.82) (**Table 4**). The goodness of fit of the risk score model was also confirmed by the Hosmer–Lemeshow test (p = 0.59). Validation of the PEP risk scoring system The risk score was associated with PEP occurrence in the validation cohort (p < 0.01, Cochran–Armitage trend test) (**Table 3**). We found that 2.4% (8/331) of the patients at low risk, 5.3% (27/513) of those at moderate risk, and 18.0% (29/161) of those at high risk experienced PEP. The risk classification was also correlated with PEP occurrence in the validation cohort (p < 0.01, Cochran–Armitage trend test).

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

The C statistic of the risk score was 0.71, which was also high in the validation cohort (Table 4). The PEP risk score model showed good fitness according to the Hosmer–Lemeshow test (p = 0.40). According to the above results, the preprocedural PEP risk could be calculated, as shown in Figure 2. Risk classification and unexpected PEP risk factors The relation between the established risk classification and intraprocedural PEP risk factors is shown in **Appendix 1-table 1**. In all patients, the development cohort, and the validation cohort, the risk classification was significantly associated with the occurrence of PEP. On the other hand, precut sphincterotomy and inadvertent pancreatic duct cannulation were not significantly associated with the occurrence of PEP. **Discussion** In this multicenter study, we created a risk scoring system (the SuPER model) using five items that could be measured before performing ERCP. With this score, PEP occurrence could be accurately predicted to some degree. Besides, the established PEP risk classification was associated with PEP occurrence independently from unpredictable intraprocedural PEP risk procedures.

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

This risk scoring and classification of PEP has several advantages. First, the score is calculated using only five items, all of which can be easily assessed by medical interviews and imaging (for example, CT). One scoring system included sphincter of Oddi dysfunction (SOD) as a test item (DiMagno et al., 2013). The diagnosis of SOD requires sphincter of Oddi manometry and fulfilment of the criteria for biliary pain, but sphincter of Oddi manometry is not widely used (Cotton et al., 2016). The diagnostic criterion for biliary pain included 8 items, and that for SOD included 15 items. Among the items of the SuPER risk scoring system, pancreatic calcification was assigned -2 points. Its low weighting could be explained by the following. The international conceptual model of CP can be divided into four stages: acute pancreatitis-recurrent acute pancreatitis, early CP, established CP, and end-stage CP (Whitcomb et al., 2016). Established CP patients have already passed the acute pancreatitis—recurrent acute pancreatitis course, and pancreatic calcification has been reported in established CP patients. Acinar dysfunction has also been observed in these patients (Whitcomb et al., 2016). Therefore, patients with pancreatic calcification may have a lower incidence of PEP. Second, the SuPER risk score can be determined before the ERCP procedure, as the established risk classification was found to be the sole significant factor

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

predicting the occurrence of PEP independent from intraprocedural PEP risk factors. As described in the Background section, precut sphincterotomy, multiple cannulation attempts, and a cannulation time greater than 10 minutes were identified as high risk factors that cannot be accounted for prior to ERCP (Testoni et al., 2010, Wang et al., 2009). Although the established PEP risk classification was independent from the included intraprocedural risk factors (precut sphincterotomy and inadvertent pancreatic duct cannulation), detailed data on the number of cannulation attempts and the cannulation time were not available. Therefore, to avoid intraoperative procedures associated with a high risk of PEP occurrence, an expert endoscopist can initially perform ERCP for high-PEP-risk patients. In addition, PEP prophylaxis can be administered beforehand for high-PEP-risk patients. As effective prophylaxes for PEP, rectal NSAIDS and pancreatic stent placement have been reported (Elmunzer et al., 2008, Murray et al., 2003, Sugimoto et al., 2019). In this report, rectal NSAID use was not identified as a significant factor preventing PEP. One reason for this is that in past reports describing the use of rectal NSAIDs to prevent PEP, patients at high risk for PEP were often treated (Elmunzer et al., 2008). In contrast, this study included all patients who underwent ERCP. Another reason might be the difference in dose. One hundred milligrams of rectal diclofenac was used in past reports, whereas 12.5-50 mg of

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

diclofenac was used in this study. In Japan, the approved diclofenac dose covered by insurance is 50 mg or less, with the dose being typically lower for elderly patients. Therefore, diclofenac doses of 12.5-50 mg were prescribed by the doctors depending on the age and size of the patients. Pancreatic stent placement itself is one of the procedures performed on the pancreatic duct and was a higher-risk procedure for PEP than endoscopic biliary procedures without an approach to the pancreatic duct (Appendix 2-table 2). Moreover, pancreatic stent placement has become a prophylactic treatment for PEP in patients who have undergone pancreatography or wire placement to the pancreatic duct (Mazaki et al., 2014, Sugimoto et al., 2019). As described above, pancreatic stent placement was performed along with high-risk-PEP procedures (i.e., guidewire placement to the pancreatic duct or pancreatography); therefore, pancreatic stent placement was grouped together with the other endoscopic retrograde pancreatography procedures as "procedures on the pancreatic duct". This study has several limitations. First, the study was retrospective, and there were missing data. However, the results reported are trustworthy. The percentage of patients who did not meet the inclusion criteria was not more than 5%, and the percentage of missing data was not over 1%. As described in the Materials and Methods section, patients with missing data for the variables selected in the risk score model

were removed from the final cohort. The reliability of the SuPER risk score model was also statistically confirmed. Second, some factors cannot be assessed before ERCP.

Additional procedures could be conducted during ERCP, and unplanned pancreatography is often performed in patients who are scheduled for endoscopic cholangiography or biliary treatment. However, the established PEP risk classification was independent from the included intraprocedural risk factors. A planned procedure for accessing the pancreatic duct is listed in the SuPER risk model. Therefore, we can predict the SuPER risk score and classification of patients regardless of whether they have undergone pancreatic duct procedures. Third, this study was performed in a single country. Validation studies over wider geographic regions are necessary.

In conclusion, a simple and useful PEP scoring system (SuPER model) with only five clinical items was developed in this multicenter study. This scoring system may aid in predicting and explaining PEP risk and in selecting appropriate prophylaxes for PEP and endoscopic pancreaticobiliary procedures for each patient.

Acknowledgements

We thank all the staff at the Department of Gastroenterology of Fukushima Medical
University, the Department of Endoscopy of Fukushima Medical University Hospital,

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

Author contributions

the Department of Gastroenterology of Fukushima Rosai Hospital, the Department of Gastroenterology of Aizu Medical Center, Fukushima Medical University, the Department of Gastroenterology of Ohtanishinouchi Hospital, Koriyama, the Department of Gastroenterology of Fukushima Redcross Hospital, the Department of Gastroenterology of Soma General Hospital, the Department of Gastroenterology of Saiseikai Fukushima General Hospital, and the Gastroenterology Ward of Fukushima Medical University Hospital. We also thank American Journal Experts for providing English language editing services. **Additional information** Competing interests The authors declare that they have no competing interests to report. **Funding** None.

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

M.S. wrote the paper, designed and performed the research. T.T. wrote the paper, designed and oversaw the research. T.S., H.S., G.S., Y.S., Y.N., Y.T., Y.N., R.K., H.I., H.A., N.K., Y.W., and H.A. performed the research. R.S. provided clinical advice. T.H. supervised the report. H.O. supervised the report and the writing of the paper. All authors read and approved the final manuscript. **Ethics** The study protocol was reviewed and approved by the Institutional Review Board of Fukushima Medical University (Number 2453). The analysis used anonymous clinical data obtained after all the participants agreed to treatment by written consent, so patients were not required to give informed consent for the study. The details of the study can be found on the homepage of Fukushima Medical University. Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

References 340 341 Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. 2007. Incidence rates of post-ERCP complications: a systematic 342 343 survey of prospective studies. American Journal of Gastroenterology **102**:1781-1788. DOI: 10.1111/j.1572-0241.2007.01279.x 344 Beyer G, Kasprowicz F, Hannemann A, Aghdassi A, Thamm P, Volzke H, Lerch MM, 345 346 Kühn JP, Mayerle J. 2023. Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a 347 population-based, cross-sectional cohort study. Gut 72:1738-1744. DOI: 348 349 10.1136/gutjnl-2021-326106, PMID: PMC10423481 350 Chiba M, Kato M, Kinoshita Y, Shimamoto N, Tomita Y, Abe T, Kanazawa K, 351 Tsukinaga S, Nakano M, Torisu Y, Toyoizumi H, Sumiyama K. 2021. The milestone for preventing post-ERCP pancreatitis using novel simplified 352 predictive scoring system: a propensity score analysis. Surgical Endoscopy 353 **35**:6696-6707. DOI: 10.1007/s00464-020-08173-4 354 Cotton PB, Elta GH, Carter CR, Pasricha PJ, Corazziari ES. 2016. Rome IV. 355 356 Gallbladder and Sphincter of Oddi Disorders. Gastroenterology. DOI: 10.1053/j.gastro.2016.02.033 357

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. 1991. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointestinal Endoscopy 37:383-393 DiMagno MJ, Spaete JP, Ballard DD, Wamsteker EJ, Saini SD. 2013. Risk models for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP): smoking and chronic liver disease are predictors of protection against PEP. Pancreas 42:996-1003. DOI: 10.1097/MPA.0b013e31827e95e9, PMID: PMC3701741 Ding X, Zhang F, Wang Y. 2015. Risk factors for post-ERCP pancreatitis: A systematic review and meta-analysis. Surgeon 13:218-229. DOI: 10.1016/j.surge.2014.11.005 Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. 2008. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut **57**:1262-1267. DOI: 10.1136/gut.2007.140756 Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. 2001. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointestinal Endoscopy 54:425-434

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. 1996. Complications of endoscopic biliary sphincterotomy. New England Journal of Medicine 335:909-918. DOI: 10.1056/nejm199609263351301 Friedland S, Soetikno RM, Vandervoort J, Montes H, Tham T, Carr-Locke DL. 2002. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy 34:483-488. DOI: 10.1055/s-2002-32004 Fujita K, Yazumi S, Matsumoto H, Asada M, Nebiki H, Matsumoto K, Maruo T, Takenaka M, Tomoda T, Onoyama T, Kurita A, Ueki T, Katayama T, Kawamura T, Kawamoto H. 2022. Multicenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post-endoscopic retrograde cholangiopancreatography pancreatitis. Digestive Endoscopy 34:1198-1204. DOI: 10.1111/den.14225, PMID: PMC9540598 Fujita K, Yazumi S, Uza N, Kurita A, Asada M, Kodama Y, Goto M, Katayama T, Anami T, Watanabe A, Sugahara A, Mukai H, Kawamura T. 2021. New practical scoring system to predict post-endoscopic retrograde cholangiopancreatography pancreatitis: Development and validation. JGH Open 5:1078-1084. DOI:

10.1002/jgh3.12634, PMID: PMC8454475 394 395 Glomsaker T, Hoff G, Kvaloy JT, Soreide K, Aabakken L, Soreide JA. 2013. Patterns 396 and predictive factors of complications after endoscopic retrograde 397 cholangiopancreatography. Br J Surg 100:373-380. DOI: 10.1002/bjs.8992 Harewood GC, Pochron NL, Gostout CJ. 2005. Prospective, randomized, controlled 398 trial of prophylactic pancreatic stent placement for endoscopic snare excision of 399 400 the duodenal ampulla. Gastrointestinal Endoscopy 62:367-370. DOI: 10.1016/j.gie.2005.04.020 401 Ishiwatari H, Hayashi T, Ono M, Sato T, Kato J. 2013. Newly designed plastic stent for 402 endoscopic placement above the sphincter of Oddi in patients with malignant 403 404 hilar biliary obstruction. *Digestive Endoscopy* **25 Suppl 2**:94-99. DOI: 405 10.1111/den.12080 406 Itoi T, Ryozawa S, Katanuma A, Okabe Y, Kato H, Horaguchi J, Tsuchiya T, Gotoda T, Fujita N, Yasuda K, Igarashi Y, Fujimoto K. 2018. Japan Gastroenterological 407 408 Endoscopy Society guidelines for endoscopic papillary large balloon dilation. Digestive Endoscopy **30**:293-309. DOI: 10.1111/den.13029 409 410 Kato S, Kuwatani M, Onodera M, Kudo T, Sano I, Katanuma A, Uebayashi M, Eto K, Fukasawa M, Hashigo S, Iwashita T, Yoshida M, Taya Y, Kawakami H, Kato H, 411

Nakai Y, Kobashigawa K, Kawahata S, Shinoura S, Ito K, Kubo K, Yamato H, 412 Hara K, Maetani I, Mukai T, Shibukawa G, Itoi T. 2022. Risk of Pancreatitis 413 414 Following Biliary Stenting With/Without Endoscopic Sphincterotomy: A 415 Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 416 **20**:1394-1403 e1391. DOI: 10.1016/j.cgh.2021.08.016 Katsinelos P, Lazaraki G, Chatzimavroudis G, Gkagkalis S, Vasiliadis I, Papaeuthimiou 417 A, Terzoudis S, Pilpilidis I, Zavos C, Kountouras J. 2014. Risk factors for 418 therapeutic ERCP-related complications: an analysis of 2,715 cases performed 419 by a single endoscopist. Ann Gastroenterol 27:65-72, PMID: PMC3959534 420 Kochar B, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, Khashab MA, 421 422 Kalloo AN, Singh VK. 2015. Incidence, severity, and mortality of post-ERCP 423 pancreatitis: a systematic review by using randomized, controlled trials. Gastrointestinal Endoscopy **81**:143-149 e149. DOI: 10.1016/j.gie.2014.06.045 424 Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, De 425 426 Bernardin M, Ederle A, Fina P, Fratton A. 1998. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest 427 428 Endosc 48:1-10 Masci E, Mariani A, Curioni S, Testoni PA. 2003. Risk factors for pancreatitis following 429

endoscopic retrograde cholangiopancreatography: a meta-analysis. *Endoscopy* 430 431 **35**:830-834. DOI: 10.1055/s-2003-42614 432Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, Minoli G, Crosta C, 433 Comin U, Fertitta A, Prada A, Passoni GR, Testoni PA. 2001. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. American 434 *Journal of Gastroenterology* **96**:417-423. DOI: 435 10.1111/j.1572-0241.2001.03594.x 436 Mazaki T, Mado K, Masuda H, Shiono M. 2014. Prophylactic pancreatic stent 437 placement and post-ERCP pancreatitis: an updated meta-analysis. *Journal of* 438 Gastroenterology 49:343-355. DOI: 10.1007/s00535-013-0806-1 439 440 Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. 2003. Diclofenac reduces the 441 incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 124:1786-1791. DOI: 442443 10.1016/s0016-5085(03)00384-6 444 Sarner M, Cotton PB. 1984. Classification of pancreatitis. *Gut* 25:756-759. DOI: 10.1136/gut.25.7.756, PMID: PMC1432589 445 446 Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimito M, Hikichi T, Ohira H. 2019. 447

Pancreatic stents to prevent post-endoscopic retrograde 448 cholangiopancreatography pancreatitis: A meta-analysis. World J Metaanal 449 7:249-258 450 451 Testoni PA, Mariani A, Giussani A, Vailati C, Masci E, Macarri G, Ghezzo L, Familiari L, Giardullo N, Mutignani M, Lombardi G, Talamini G, Spadaccini A, Briglia R, 452 Piazzi L. 2010. Risk factors for post-ERCP pancreatitis in high- and low-volume 453 454 centers and among expert and non-expert operators: a prospective multicenter study. *American Journal of Gastroenterology* **105**:1753-1761. DOI: 455 10.1038/ajg.2010.136 456 Wang P, Li ZS, Liu F, Ren X, Lu NH, Fan ZN, Huang Q, Zhang X, He LP, Sun WS, 457 Zhao Q, Shi RH, Tian ZB, Li YQ, Li W, Zhi FC. 2009. Risk factors for 458 459 ERCP-related complications: a prospective multicenter study. American Journal of Gastroenterology 104:31-40. DOI: 10.1038/ajg.2008.5 460 461 Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, Shimosegawa T. 462 2016. Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. *Pancreatology* **16**:218-224. DOI: 463 464 10.1016/j.pan.2016.02.001, PMID: PMC6042966 Williams EJ, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, Riley SA, Veitch 465

466 P, Wilkinson ML, Williamson PR, Lombard M. 2007. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter 467 study. Endoscopy 39:793-801. DOI: 10.1055/s-2007-966723 468 469 Wynants L, Bouwmeester W, Moons KG, Moerbeek M, Timmerman D, Van Huffel S, Van Calster B, Vergouwe Y. 2015. A simulation study of sample size 470 demonstrated the importance of the number of events per variable to develop 471 prediction models in clustered data. Journal of Clinical Epidemiology 472**68**:1406-1414. DOI: 10.1016/j.jclinepi.2015.02.002 473 474 Zheng R, Chen M, Wang X, Li B, He T, Wang L, Xu G, Yao Y, Cao J, Shen Y, Wang Y, Zhu H, Zhang B, Wu H, Zou X, He G. 2020. Development and validation of a 475 risk prediction model and scoring system for post-endoscopic retrograde 476 477cholangiopancreatography pancreatitis. Ann Transl Med 8:1299. DOI: 10.21037/atm-20-5769, PMID: PMC7661903 478 479 480 481

Figure legends 482 483 Figure 1. Flowchart of the inclusion criteria. ERCP, endoscopic retrograde cholangiopancreatography. 484 485 Figure 2. Example of the preprocedural PEP risk checklist. ERCP, endoscopic retrograde cholangiopancreatography. IPMN, intraductal papillary mucinous neoplasm; 486 PEP, post-ERCP pancreatitis. 487

Tables

490

Table 1. Comparison of patient characteristics and ERCP outcomes between the development and validation cohorts.

	Development	Validation	P value
	cohort	cohort	
	(n=1037)	(n=1037)	
Patient factors			
Age, y, mean \pm SD	73.8 ± 12.7	75.1 ± 12.5	0.02
Sex, n, male/female	642/395	629/408	0.59
History of pancreatitis, n (%)	73 (7.0)	45 (4.4)	0.01
History of PEP, n (%)	26 (2.5)	24 (2.3)	0.89
History of gastrectomy, n (%)	82 (7.9)	88 (8.5)	0.69
Billroth-I reconstruction, n	24	25	
Billroth-II reconstruction, n	23	25	
Roux-en-Y reconstruction, n	33	36	
Double tract, n	1	1	
Gastric tube reconstruction, n	1	1	
Pancreatic cancer, n (%)	145 (14.0)	174 (16.8)	0.09
IPMN, n (%)	17 (1.6)	8 (0.8)	0.11
Native papilla of Vater, n (%)	535 (51.6)	494 (47.7)	0.08
Total bilirubin, mg/dl, mean ± SD	3.5 ± 5.3	3.6 ± 5.0	0.45
Diameter of the MPD, mm, mean \pm SD ^a	2.84 ± 2.63	3.1 ± 2.9	0.10
Pancreatic calcification, n (%) ^b	107 (10.6)	87 (8.7)	0.15
Periampullary diverticulum, n (%)	207 (20.0)	224 (21.6)	0.39
Pre-ERCP prophylaxis			
Gabexate or Nafamostat, n (%)	709 (68.4)	703 (67.8)	0.81
Intravenous hydration, n (%)	22 (2.1)	14 (1.4)	0.24
NSAID suppository, n (%)	53 (5.1)	45 (4.3)	0.47
Factors related to the planned procedure			
EST, n (%)	449 (43.3)	434 (41.9)	0.53
EPBD, n (%)	31 (3.0)	40 (3.9)	0.33
EPLBD, n (%)	56 (5.4)	55 (5.3)	1.0
Biliary stone removal, n (%)	327 (31.5)	342 (33.0)	0.51

Ampullectomy, n (%)	5 (0.5)	5 (0.5)	1.0
Biliary stent, n (%)	594 (57.3)	611(58/9)	0.48
Plastic stent, n (%)	445 (42.9)	436 (42.0)	0.72
SEMS, n (%)	119 (11.5)	122 (11.8)	0.89
CSEMS, n (%)	36 (3.5)	44 (4.2)	0.43
Biliary stent above the papilla, n (%)	45 (4.3)	47 (4.5)	0.92
Procedures on the pancreatic duct, n	285 (27.5)	237 (22.9)	0.017
(%)			
PEP occurrence, n (%)	70 (6.8)	64 (6.2)	0.66
Mild, n	60	53	
Moderate, n	8	7	
Severe, n	2	4	

ERCP, endoscopic retrograde cholangiopancreatography; SD, standard deviation; PEP, post-ERCP pancreatitis; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation; SEMS, self-expandable metallic stent; CSEMS, covered SEMS.

492 493

494 495

496

^a Data were available for 1671 patients.

^b Data were available for 2017 patients.

Table 2. Logistic regression analysis of predictive factors for PEP in the development cohort.

	Univariate analysis			Multivariate analysis				
	OR	95% CI	P value	OR	95% CI	P value	Regression coefficient	Points
Age < 50 years	2.42	0.99-6.0	0.053	1.76	0.67-4.63	0.25	0.56	-
Female	1.91	1.17-3.10	< 0.01	1.72	1.03-2.89	0.039	0.55	1
History of pancreatitis	1.26	0.53-3.0	0.61					
History of PEP	1.84	0.54-6.28	0.33					
History of gastrectomy	0.89	0.35-2.27	0.81					
Pancreatic cancer	1.03	0.51-2.06	0.94					
IPMN	8.15	2.92-22.7	< 0.01	3.04	0.97-9.52	0.056	1.11	2
Native papilla of Vater	4.49	2.42-8.30	< 0.01	2.72	1.30-5.71	< 0.01	1.0	2
Total bilirubin $\leq 1.2 \text{ mg/dl}$	1.13	0.69-1.84	0.62					
Diameter of the MPD > 3 mm ^a	1.31	0.76-2.25	0.33					
Pancreatic calcification ^b	0.36	0.11-1.17	0.089	0.32	0.10-1.1	0.072	-1.13	-2
Periampullary diverticulum	0.65	0.33-1.30	0.22					
Gabexate or Nafamostat	0.72	0.44-1.19	0.20					
Intravenous hydration	1.39	0.32-6.08	0.66					
NSAID suppository before ERCP	1.47	0.57-3.83	0.43					
EST	1.71	1.05-2.79	0.03	0.83	0.45-1.52	0.54	-0.19	-
EPBD	< 0.01	0-Infinity	0.98					
EPLBD	0.24	0.03-1.76	0.16					
Biliary stone removal	0.68	0.39-1.19	0.18					

Ampullectomy	3.49	0.39-31.6	0.27					
Biliary stent	0.93	0.57-1.52	0.78					
Plastic stent	0.72	0.44-1.20	0.21					
SEMS	1.66	0.87-3.20	0.13					
CSEMS	0.81	0.19-3.43	0.77					
Biliary stent above the papilla	0.30	0.04-2.24	0.24					
Procedures on the pancreatic duct	4.77	2.89-7.89	< 0.01	3.49	1.99-6.12	< 0.01	1.25	2

PEP, post—endoscopic retrograde cholangiopancreatography pancreatitis; OR, odds ratio; CI, confidence interval; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation; EPLBD, endoscopic papillary large balloon dilation; SEMS, self-expandable metallic stent; CSEMS, covered SEMS.

^a Data were available for 985 patients in the development cohort.

^b Data were available for 1012 patients in the development cohort.

Table 3. Patient distribution in terms of risk score and classification.

Risk score		Developr	ment cohort ($n = 1012$)	a	Validation cohort (n = 1005) ^b			
		PEP occurrence,	PEP rate (95% CI)	P value c	PEP occurrence,	PEP rate (95% CI)	P value c	
		N	(%)		N	(%)		
-2		0/29	0 (0-11.9)	< 0.01	0/33	0 (0-10.6)	< 0.01	
-1		0/9	0 (0-33.6)		0/5	0 (0-52.2)		
0		0/289	0 (0-1.3)		8/293	2.7 (1.2-5.3)		
1		6/140	4.3 (1.6-9.1)		5/160	3.1 (1.0-7.1)		
2		8/202	4.0 (1.7-7.7)		14/195	7.2 (4.0-11.8)		
3		13/150	8.7 (4.7-14.4)		8/158	5.1 (2.2-9.7)		
4		18/97	18.6 (11.4-27.7)		14/84	16.7 (9.4-26.4)		
5		17/83	20.5 (12.4-30.8)		14/71	19.7 (11.2-30.9)		
6		3/9	33.3 (7.5-70.1)		0/3	0 (0-70.8)		
7		1/4	25.0 (0.6-80.6)		1/3	33.3 (0.8-90.6)		
Risk	Risk	PEP occurrence,	PEP rate (95% CI)	P value c	PEP occurrence,	PEP rate (95% CI)	P value c	
classification	score	N	(%)		N	(%)		
Low	≤ 0	0/327	0 (0-1.1)	< 0.01	8/331	2.4 (1.0-4.7)	< 0.01	
Moderate	1-3	27/492	5.5 (3.6-7.9)		27/513	5.3 (3.5-7.6)		
High	4-7	39/193	20.2 (14.8-26.6)		29/161	18.0 (12.4-24.8)		

⁵⁰⁹ PEP, post–endoscopic retrograde cholangiopancreatography pancreatitis; CI, confidence interval.

^{510 &}lt;sup>a</sup> There were missing data for 25 patients.

⁵¹¹ b There were missing data for 32 patients.


^c The correlations between the risk score or classification and PEP occurrence were evaluated by the Cochran–Armitage test.

Table 4. Goodness of fit of the risk score model.

	Development cohort	Validation cohort
C-statistic (95% CI)	0.77 (0.72–0.82)	0.71 (0.64–0.78)
Hosmer–Lemeshow test, p value	0.59	0.40

CI, confidence interval.

515



Preprocedural risk score for Post-ERCP pancreatitis

1. Please check the corresponding items and calculate the total score.

Risk factors	Points	
☐ Female sex	1	
□ Native papilla of Vater	2	
☐ Pancreatic calcification on imaging	-2	
	2	
☐ Planned pancreatic duct procedures	2 Total	points

2. Please find the predictive post-ERCP pancreatitis rate according to the total score.

Total points	Risk group	Predictive post-ERCP pancreatitis rate
≤ 0	Low	0-2%
1-3	Moderate	5%
4-7	High	18-20%

XThe post-ERCP pancreatitis rate might change due to the actual ERCP procedure performed.